Nothing Special   »   [go: up one dir, main page]

CO5140096A1 - Vehiculo viscoso de una fase para la suspension de principios activos - Google Patents

Vehiculo viscoso de una fase para la suspension de principios activos

Info

Publication number
CO5140096A1
CO5140096A1 CO00007997A CO00007997A CO5140096A1 CO 5140096 A1 CO5140096 A1 CO 5140096A1 CO 00007997 A CO00007997 A CO 00007997A CO 00007997 A CO00007997 A CO 00007997A CO 5140096 A1 CO5140096 A1 CO 5140096A1
Authority
CO
Colombia
Prior art keywords
vehicle
aqueous
stable
viscose
suspension
Prior art date
Application number
CO00007997A
Other languages
English (en)
Spanish (es)
Inventor
Stephen A Berry
Pamela J Fereira
Houdin Dehnad
Anna Muchnik
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22382917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5140096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of CO5140096A1 publication Critical patent/CO5140096A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO00007997A 1999-02-08 2000-02-08 Vehiculo viscoso de una fase para la suspension de principios activos CO5140096A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11917099P 1999-02-08 1999-02-08

Publications (1)

Publication Number Publication Date
CO5140096A1 true CO5140096A1 (es) 2002-03-22

Family

ID=22382917

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00007997A CO5140096A1 (es) 1999-02-08 2000-02-08 Vehiculo viscoso de una fase para la suspension de principios activos

Country Status (22)

Country Link
EP (2) EP1666026B2 (de)
JP (1) JP4861551B2 (de)
KR (2) KR20080045300A (de)
CN (1) CN1232244C (de)
AR (1) AR029613A1 (de)
AT (2) ATE322889T1 (de)
AU (1) AU775904B2 (de)
CA (1) CA2361424C (de)
CO (1) CO5140096A1 (de)
CY (1) CY1119950T1 (de)
DE (1) DE60027272T2 (de)
DK (1) DK1666026T4 (de)
ES (2) ES2261190T3 (de)
HK (2) HK1041451B (de)
HU (1) HUP0200202A3 (de)
IL (1) IL144755A0 (de)
NO (1) NO20013861L (de)
NZ (1) NZ513441A (de)
PT (2) PT1666026E (de)
TW (2) TWI292716B (de)
WO (1) WO2000045790A2 (de)
ZA (1) ZA200106443B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
WO2004056338A2 (en) * 2002-12-19 2004-07-08 Alza Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
BRPI0408862A (pt) 2003-03-31 2006-04-11 Alza Corp bomba osmótica com dispositivo para dissipar pressão interna
WO2004089335A2 (en) * 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20060263433A1 (en) * 2005-02-03 2006-11-23 Ayer Rupal A Suspension formulation of interferon
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
EP2359808B1 (de) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotisches Verabreichungssystem mit Kolbenanordnung
AU2008244523B2 (en) * 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2170283B1 (de) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Bildung eines stabilen submikron-peptids oder von proteinteilchen durch dünnfilm-gefrieren
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US8779094B2 (en) 2008-11-16 2014-07-15 Board Of Regents, The University Of Texas System Low viscosity highly concentrated suspensions
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
AU2011229235B2 (en) 2010-03-17 2014-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de) 2010-11-11 2012-06-13 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2834855C (en) 2011-05-25 2020-12-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
EP2714008B1 (de) 2011-05-25 2016-12-14 Novaliq GmbH Pharmazeutische zusammensetzung zur verabreichung an nägel
PE20141413A1 (es) 2011-10-25 2014-10-25 Onclave Therapeutics Ltd Formulaciones de anticuerpo y metodos
PL2806886T3 (pl) 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
PL3181119T3 (pl) 2012-09-12 2020-01-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki
EP3100722B1 (de) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorierte alkane zur solubilisierung von meibum
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
AU2016329261B2 (en) 2015-09-30 2020-05-07 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
DK3495023T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh Semifluorerede forbindelser og sammensætninger deraf
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
PL3442480T3 (pl) 2016-06-23 2020-04-30 Novaliq Gmbh Sposób podawania miejscowego
MX2019003363A (es) 2016-09-22 2019-10-02 Novaliq Gmbh Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
JP7072582B2 (ja) 2017-04-21 2022-05-20 ノバリック ゲーエムベーハー ヨウ素組成物
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
SG11202007858VA (en) 2018-03-02 2020-09-29 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2020064556A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Topical sunscreen formulation
US12029757B2 (en) 2018-09-27 2024-07-09 Dermaliq Therapeutics, Inc. Lipid barrier repair
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) † 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
JPS5788115A (en) * 1980-10-06 1982-06-01 Miles Lab Stable non-aqueous solution of tetracycline antibiotic salt
DE3320583A1 (de) † 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS61189230A (ja) * 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd エトポシド製剤
GB8528959D0 (en) * 1985-11-25 1986-01-02 Leo Pharm Prod Ltd Chemical compounds
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
JPH0720866B2 (ja) † 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
JP2794022B2 (ja) † 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
JPH03236317A (ja) † 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5733572A (en) † 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0520119A1 (de) † 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
WO1993009763A1 (en) † 1991-11-15 1993-05-27 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5314685A (en) † 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
AU6410494A (en) † 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
AU7396294A (en) † 1993-06-25 1995-01-24 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
ATE183926T1 (de) † 1993-09-29 1999-09-15 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
CA2203566C (en) * 1994-10-24 2001-10-23 Yuko Hosokawa Percutaneously administration preparation
US5736159A (en) † 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
PL184820B1 (pl) * 1995-06-06 2002-12-31 Hoffmann La Roche Dawka jednostkowa kompozycji farmaceutycznej do leczenia chorób wywoływanych przez HIV
WO1996040355A1 (en) † 1995-06-07 1996-12-19 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5904935A (en) † 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6572879B1 (en) † 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5906830A (en) † 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5766620A (en) † 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
DE69735656T2 (de) † 1996-07-15 2006-08-24 Alza Corp., Mountain View Vorrichtung zur transdermalen Verabreichung von Fluoxetin
DK0934078T3 (da) † 1996-10-24 2003-04-14 Alza Corp Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf
DE19646392A1 (de) † 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
JP4642946B2 (ja) † 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US20020039594A1 (en) † 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
SI9700186B (sl) † 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin

Also Published As

Publication number Publication date
KR100858856B1 (ko) 2008-09-17
HUP0200202A3 (en) 2009-08-28
HK1094528A1 (en) 2007-04-04
TW200730199A (en) 2007-08-16
NO20013861L (no) 2001-09-20
ATE322889T1 (de) 2006-04-15
EP1666026B2 (de) 2015-02-25
DE60027272D1 (de) 2006-05-24
CA2361424C (en) 2009-04-28
CN1339962A (zh) 2002-03-13
EP1666026A3 (de) 2007-08-08
HK1041451A1 (en) 2002-07-12
EP1666026B1 (de) 2011-12-21
HUP0200202A2 (hu) 2002-05-29
ES2261190T3 (es) 2006-11-16
ES2379471T5 (es) 2015-05-26
KR20010101842A (ko) 2001-11-14
EP1666026A2 (de) 2006-06-07
KR20080045300A (ko) 2008-05-22
TWI292716B (en) 2008-01-21
EP1152749B1 (de) 2006-04-12
JP2002536315A (ja) 2002-10-29
CN1232244C (zh) 2005-12-21
HK1041451B (zh) 2006-12-01
DK1666026T4 (da) 2015-05-04
IL144755A0 (en) 2002-06-30
ATE537811T1 (de) 2012-01-15
DK1666026T3 (da) 2012-04-10
JP4861551B2 (ja) 2012-01-25
NZ513441A (en) 2004-01-30
AU3481600A (en) 2000-08-25
DE60027272T2 (de) 2007-01-25
WO2000045790A3 (en) 2000-12-07
AU775904B2 (en) 2004-08-19
ZA200106443B (en) 2002-08-06
AR029613A1 (es) 2003-07-10
CA2361424A1 (en) 2000-08-10
PT1666026E (pt) 2012-03-15
PT1152749E (pt) 2006-08-31
EP1152749A2 (de) 2001-11-14
WO2000045790A2 (en) 2000-08-10
CY1119950T1 (el) 2018-12-12
NO20013861D0 (no) 2001-08-08
ES2379471T3 (es) 2012-04-26

Similar Documents

Publication Publication Date Title
CO5140096A1 (es) Vehiculo viscoso de una fase para la suspension de principios activos
JP6759335B2 (ja) カルボキシメチルキトサンスポンジ配合物
ATE209907T1 (de) Flüssige mittel zur wirkstoffabgabe
KR870006893A (ko) 고점성 하이드로겔 또는 그 현탁액의 약학적 제제
BR9913170A (pt) Composição de xampu condicionador do cabelo, e, processo para o tratamento de cabelo
BR0001919A (pt) Composição de creme de limpeza de pele de modo que forme espuma, e, sistema de limpeza espumante de pele.
CA2148583A1 (en) Viscoelastic Surfactant Based Foam Fluids
ES2062786T3 (es) Microesferas, su procedimiento de preparacion y su utilizacion.
WO2002045662A3 (en) Anhydrous creams, lotions and gels
BR9914977A (pt) Composição para liberação modificada demulti-partìculas
BR0114782A (pt) Composição de copolìmero, processo para preparar a mesma, composição aquosa, produtos, composição contendo agente terapêutico, composição de eletrólito e uso da composição de copolìmero
BR0111194A (pt) Sistemas absorventes especìficos para menstruação
EP1345636A1 (de) Wasserfreier, hydrophiler absorbierender wundverband
ATE509637T1 (de) Temperaturgesteuerte verabreichungssysteme
BR9911849A (pt) Composição espumante para o cuidado dos cabelos e uso da mesma
DE60026618D1 (de) Gamma-ifn flüssigtropfenaerosol und verfahren
BR0015538A (pt) Emprego de polissiloxanos com grupos amino quaternários como coadjuvantes de formulação, e agentes contendo-os
AR039991A1 (es) Composiciones para champu
DK1189595T3 (da) Ophthalmiske sammensætninger i form af vandige geler
AR040747A1 (es) Un sistema de suministro percutaneo
DE59912602D1 (de) Vorrichtung zur freigabe von stoffen
Kaufman The use of tissue adhesive (isobutyl cyanoacrylate) and topical steroid (0.1 percent dexamethasone) in experimental tympanoplasty
ES2193562T3 (es) Dispositivo de dosificacion.
KR102662531B1 (ko) 중합체 조성물, 전달 장치 및 방법
WO2002085325A3 (de) Herstellung und anwendung einer suspensionszusammensetzung mit einem ultraschall-kontrastmittel